Trials / Completed
CompletedNCT01266837
Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- iOMEDICO AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A single arm, open-label, multi-center phase IV clinical trial for patients with metastatic renal cell carcinoma, who have progressed on or after the first VEGF-targeted therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | 10 mg p.o once daily |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2017-09-26
- Completion
- 2017-10-31
- First posted
- 2010-12-24
- Last updated
- 2017-11-14
Locations
8 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01266837. Inclusion in this directory is not an endorsement.